For research use only
| Cat No. | ABC-X0019C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocyte |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The HRAS (G13D) BAF3 cell line provides a powerful tool for studying tumorigenesis mechanisms, supporting drug development and validation of RAS treatment.
Human HRAS (G13D) BAF3 Cell Line is a genetically engineered model derived from selected murine Ba/F3 parental cell line based on customers’ requirement. HRAS (G13D) BAF3 mutant cell line is generated by stable integration of exogenous human HRAS gene harboring the G13D point mutation into Ba/F3 host cells using our optimized transduction of lentiviral vectors.
Target
HRAS encodes a member of the RAS GTPase family that regulates cell proliferation and differentiation through the MAPK and PI3K signaling pathways. The G13D mutation results in constitutive activation of HRAS and is implicated in tumorigenesis across several solid cancers, including bladder and thyroid carcinomas. AcceGen offers generation of stable overexpression and RAS-mutant cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0019C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The HRAS (G13D) BAF3 Cell Line serves as a powerful tool to investigate RAS mutation-driven oncogenesis and therapeutic sensitivity. This model enables mechanistic studies of downstream MAPK/ERK activation, IL-3-independent transformation, and resistance to RAS pathway inhibitors. It is utilized for drug discovery and validation of anti-RAS therapeutic strategies.